Physician profile
Mohammed Berrou
NPI 1811283740
$7,637.38
in general payments reported to CMS, 2019-2025
33 companies · $676 in 2025
The $676 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $200 · 2020: $79.16 · 2021: $74.85 · 2022: $416 · 2023: $329 · 2024: $5,862 · 2025: $676.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $4,017 · Food and Beverage: $1,855 · Travel and Lodging: $995.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $4,017.38 |
| Food and Beverage | $1,854.92 |
| Travel and Lodging | $994.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $5,011.55 | 2024 | |
| Glaxosmithkline, LLC. | $400.24 | 2019-2025 | Arexvy, Nucala, Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $221.77 | 2019-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $194.44 | 2019-2025 | Fasenra, Airsupra, Symbicort |
| Amgen INC. | $187.78 | 2022-2025 | Tezspire, Tavneos |
| United Therapeutics Corporation | $154.09 | 2022-2025 | Tyvaso, Tyvaso |
| Mylan Specialty L.P. | $151.73 | 2019-2024 | Yupelri |
| Inspire Medical Systems, INC. | $147.19 | 2024 | Inspire |
| Actelion Pharmaceuticals US, INC. | $142.58 | 2019-2025 | Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.90 | 2020-2024 | Ofev, Stiolto Respimat |
| Merck Sharp & Dohme LLC | $109.73 | 2019-2025 | Zerbaxa, Keytruda, Winrevair |
| Genzyme Corporation | $103.74 | 2022-2025 | |
| Resmed Corp | $83.75 | 2023-2025 | |
| Baxter Healthcare | $78.23 | 2022-2024 | Hillrom - Vest System Model 105 Home Care |
| Takeda Pharmaceuticals U.S.A., INC. | $66.97 | 2022-2024 | Glassia |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $61.06 | 2020-2024 | Xywav |
| Grifols USA, LLC | $46.78 | 2019-2024 | Prolastin-C Liquid |
| Lilly USA, LLC | $39.06 | 2025 | Zepbound |
| Verona Pharma, INC. | $34.35 | 2025 | Ohtuvayre |
| Insmed, INC. | $32.49 | 2024-2025 | Brinsupri, Arikayce |
| Pulmonx Corporation | $29.47 | 2025 | Zephyr Delivery Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Harmony Biosciences LLC | $26.56 | 2023 | Wakix |
| Avadel Cns Pharmaceuticals, LLC | $26.34 | 2025 | Lumryz |
| Astellas Pharma US INC | $22.19 | 2025 | Cresemba |
| Genentech USA, INC. | $21.14 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.98 | 2024 | |
| Mallinckrodt Hospital Products INC. | $17.66 | 2020 | |
| 3b Medical, INC. | $17.62 | 2025 | Luna |
| Electromed, INC. | $17.03 | 2025 | Smartvest |
| Circassia INC. | $16.55 | 2019 | |
| Gilead Sciences, INC. | $16.09 | 2021 | |
| Abbvie INC. | $15.92 | 2022 | |
| Bard Access Systems, INC. | $12.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Berrou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.